Your browser doesn't support javascript.
loading
Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression.
Azzu, Vian; Vacca, Michele; Kamzolas, Ioannis; Hall, Zoe; Leslie, Jack; Carobbio, Stefania; Virtue, Samuel; Davies, Susan E; Lukasik, Agnes; Dale, Martin; Bohlooly-Y, Mohammad; Acharjee, Animesh; Lindén, Daniel; Bidault, Guillaume; Petsalaki, Evangelia; Griffin, Julian L; Oakley, Fiona; Allison, Michael E D; Vidal-Puig, Antonio.
Afiliação
  • Azzu V; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Liver Unit, Cambridge NIHR Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Gastroenterology and Hepatology, Norfol
  • Vacca M; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK; Clinica Medica Cesare Frugoni, Department of Interdisciplinary Medicine
  • Kamzolas I; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, UK.
  • Hall Z; Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK; Biomolecular Medicine, Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Leslie J; Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, 5 Newcastle University, Newcastle upon Tyne, UK.
  • Carobbio S; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Virtue S; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Davies SE; Department of Pathology, Cambridge University Hospitals, Cambridge, UK.
  • Lukasik A; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Dale M; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Bohlooly-Y M; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Acharjee A; Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK; College of Medical and Dental Sciences, Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, UK.
  • Lindén D; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Division of Endocrinology, Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Bidault G; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Petsalaki E; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, UK.
  • Griffin JL; Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK; Biomolecular Medicine, Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Oakley F; Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, 5 Newcastle University, Newcastle upon Tyne, UK.
  • Allison MED; Liver Unit, Cambridge NIHR Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: michael.allison@addenbrookes.nhs.uk.
  • Vidal-Puig A; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Wellcome Trust Sanger Institute, Hinxton, UK; Cambridge University Nanjing Centre of Technology and Innovation, Jiangbei, Nanjing, China. Electronic address: ajv22@medschl.cam.
Mol Metab ; 48: 101210, 2021 06.
Article em En | MEDLINE | ID: mdl-33722690
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colesterol / Progressão da Doença / Peptídeos e Proteínas de Sinalização Intracelular / Lipogênese / Hepatopatia Gordurosa não Alcoólica / Proteínas de Membrana Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Metab Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colesterol / Progressão da Doença / Peptídeos e Proteínas de Sinalização Intracelular / Lipogênese / Hepatopatia Gordurosa não Alcoólica / Proteínas de Membrana Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Metab Ano de publicação: 2021 Tipo de documento: Article